UY34856A - Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida - Google Patents
Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamidaInfo
- Publication number
- UY34856A UY34856A UY34856A UY34856A UY34856A UY 34856 A UY34856 A UY 34856A UY 34856 A UY34856 A UY 34856A UY 34856 A UY34856 A UY 34856A UY 34856 A UY34856 A UY 34856A
- Authority
- UY
- Uruguay
- Prior art keywords
- oxo
- thiofencarboxamide
- metil
- oxazolidin
- morpholinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a una forma de presentación farmacéutica sólida de uso oral que co ntiene 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofen-carboxamida (principio activo (I) rivaroxaban), caracterizada porque una cantidad parcial del principio activo (I) se libera rápidamente y una cantidad parcial se libera en forma controlada (modificada, retardada, lenta), así como también a procedimientos para su preparación, a su aplicación como medicamento, así como también a su uso para la profilaxis, la profilaxis secundaria o el tratamiento de enfermedades
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12174797 | 2012-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34856A true UY34856A (es) | 2013-12-31 |
Family
ID=48782297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY34856A UY34856A (es) | 2012-07-03 | 2013-06-11 | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
Country Status (33)
Country | Link |
---|---|
US (2) | US20150125527A1 (es) |
EP (1) | EP2869814B1 (es) |
JP (1) | JP6166781B2 (es) |
KR (1) | KR20150027284A (es) |
CN (1) | CN104582684A (es) |
AP (1) | AP3756A (es) |
AR (1) | AR091621A1 (es) |
AU (1) | AU2013286068A1 (es) |
BR (1) | BR112015000043A2 (es) |
CA (1) | CA2878123A1 (es) |
CL (1) | CL2015000002A1 (es) |
CO (1) | CO7240379A2 (es) |
CR (1) | CR20150001A (es) |
CU (1) | CU20140152A7 (es) |
DO (1) | DOP2015000001A (es) |
EA (1) | EA025016B1 (es) |
EC (1) | ECSP14033581A (es) |
ES (1) | ES2574627T3 (es) |
GT (1) | GT201400306A (es) |
HK (1) | HK1209635A1 (es) |
IL (1) | IL236455A0 (es) |
IN (1) | IN2014DN11066A (es) |
MA (1) | MA37721B1 (es) |
MX (1) | MX2015000053A (es) |
NZ (1) | NZ703733A (es) |
PE (1) | PE20150189A1 (es) |
PH (1) | PH12014502833A1 (es) |
SG (1) | SG11201408420YA (es) |
TN (1) | TN2014000541A1 (es) |
TW (1) | TW201414508A (es) |
UY (1) | UY34856A (es) |
WO (1) | WO2014005934A1 (es) |
ZA (1) | ZA201500759B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
CA3010726A1 (en) * | 2016-02-23 | 2017-08-31 | Morgandane Scientific, LLC | Method of treating patients coadministered a factor xa inhibitor and verapamil |
CN107823166A (zh) * | 2016-09-21 | 2018-03-23 | 齐鲁制药有限公司 | 一种利伐沙班片的制备方法 |
JP2021531297A (ja) * | 2018-07-24 | 2021-11-18 | バイエル・アクチエンゲゼルシヤフト | 経口投与可能であり、修飾された放出を有する薬学的投薬形態 |
UY38308A (es) * | 2018-07-24 | 2020-02-28 | Bayer Pharma AG | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada |
US10722486B2 (en) | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
JP7465157B2 (ja) * | 2020-06-15 | 2024-04-10 | 沢井製薬株式会社 | リバーロキサバン含有口腔内崩壊錠の製造方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
KR20080083074A (ko) * | 1998-06-03 | 2008-09-12 | 알자 코포레이션 | 연장된 약물 치료를 제공하기 위한 방법 및 장치 |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
MXPA06002455A (es) * | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
RU2011104360A (ru) * | 2008-07-08 | 2012-08-20 | Рациофарм ГмбХ (DE) | Фармацевтические соединения, содержащие 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-митил)-2-тиофенкарбоксамид |
GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
MX2012015188A (es) * | 2010-06-22 | 2013-05-20 | Twi Pharmaceuticals Inc | Composiciones de liberacion controlada con efecto de alimentos reducido. |
-
2013
- 2013-06-11 UY UY34856A patent/UY34856A/es not_active Application Discontinuation
- 2013-06-28 US US14/412,487 patent/US20150125527A1/en not_active Abandoned
- 2013-06-28 NZ NZ703733A patent/NZ703733A/en not_active IP Right Cessation
- 2013-06-28 US US13/930,094 patent/US20140010876A1/en not_active Abandoned
- 2013-06-28 BR BR112015000043A patent/BR112015000043A2/pt active Search and Examination
- 2013-06-28 IN IN11066DEN2014 patent/IN2014DN11066A/en unknown
- 2013-06-28 ES ES13735235.7T patent/ES2574627T3/es active Active
- 2013-06-28 PE PE2014002579A patent/PE20150189A1/es not_active Application Discontinuation
- 2013-06-28 WO PCT/EP2013/063590 patent/WO2014005934A1/de active Application Filing
- 2013-06-28 CN CN201380035605.8A patent/CN104582684A/zh active Pending
- 2013-06-28 AP AP2015008208A patent/AP3756A/en active
- 2013-06-28 AU AU2013286068A patent/AU2013286068A1/en not_active Abandoned
- 2013-06-28 KR KR20157002492A patent/KR20150027284A/ko not_active Application Discontinuation
- 2013-06-28 CA CA2878123A patent/CA2878123A1/en not_active Abandoned
- 2013-06-28 JP JP2015519105A patent/JP6166781B2/ja not_active Expired - Fee Related
- 2013-06-28 AR ARP130102318 patent/AR091621A1/es unknown
- 2013-06-28 MX MX2015000053A patent/MX2015000053A/es unknown
- 2013-06-28 EA EA201590142A patent/EA025016B1/ru not_active IP Right Cessation
- 2013-06-28 EP EP13735235.7A patent/EP2869814B1/de active Active
- 2013-06-28 SG SG11201408420YA patent/SG11201408420YA/en unknown
- 2013-07-02 TW TW102123589A patent/TW201414508A/zh unknown
-
2014
- 2014-12-19 PH PH12014502833A patent/PH12014502833A1/en unknown
- 2014-12-25 IL IL236455A patent/IL236455A0/en unknown
- 2014-12-30 GT GT201400306A patent/GT201400306A/es unknown
- 2014-12-30 CU CU2014000152A patent/CU20140152A7/es unknown
- 2014-12-30 TN TN2014000541A patent/TN2014000541A1/fr unknown
- 2014-12-30 EC ECIEPI201433581A patent/ECSP14033581A/es unknown
- 2014-12-31 MA MA37721A patent/MA37721B1/fr unknown
- 2014-12-31 CO CO14287291A patent/CO7240379A2/es unknown
-
2015
- 2015-01-02 DO DO2015000001A patent/DOP2015000001A/es unknown
- 2015-01-02 CL CL2015000002A patent/CL2015000002A1/es unknown
- 2015-01-05 CR CR20150001A patent/CR20150001A/es unknown
- 2015-02-02 ZA ZA2015/00759A patent/ZA201500759B/en unknown
- 2015-10-23 HK HK15110431.9A patent/HK1209635A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34856A (es) | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida | |
UY34095A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
EA201590139A1 (ru) | Шприц | |
UY34765A (es) | Compuestos novedosos. | |
UY33943A (es) | Derivados espirocíclicos de isoxazolina como agentes antiparasitarios. | |
UY34804A (es) | Inhibidores del nampt | |
CL2018000649A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca | |
UY34591A (es) | Compuestos de imidazopirrolidinona | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34515A (es) | Triazolopiridinas sustituidas | |
UY34705A (es) | Películas de capas múltiples capaces de liberar ingredientes activos por un período limitado de tiempo | |
UY34818A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
EA201590272A1 (ru) | Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб | |
TWD168213S (zh) | 香水瓶 | |
UY34776A (es) | Formulaciones de bromocriptina | |
ES2721666T3 (es) | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo | |
AR088099A1 (es) | Composicion anticaspa | |
UY4281Q (es) | Juguera | |
TR201821285T4 (tr) | CCR3 antagonisti içeren farmasötik formülasyonlar. | |
UY34629A (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina | |
MX2016015010A (es) | Composiciones para el cuidado bucal que contienen polietilenglicol para estabilidad fisica. | |
UY4253Q (es) | Nuevo diseño de cajero automatico. | |
UY34842A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
UY34677A (es) | Imidazopiridazinas sustituidas | |
MX2016015008A (es) | Composiciones para el cuidado bucal que contienen polietilenglicol para estabilidad fisica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210602 |